Company intelligence / Profile preview

Mediford

Itabashi-ku, Tokyo, Japan

Ownership: Private
Employees: ~578
Development stage: Other

Overview

Mediford is a Japanese CRO offering GLP-compliant services across the drug development spectrum including non-clinical, clinical bioanalysis, and central lab operations, with increasing capabilities in biomarker analytics and neurological diagnostics. The company supports wide-ranging clinical research programs but does not operate its own clinical pipeline.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculeMonoclonal antibodyNucleic acidCell therapyGene therapyBiologic
Industry: Contract Research Organization

Partnerships

C2N Diagnostics (biomarker panels for Alzheimer's disease and neurology)

Beyond the preview

Go deeper on Mediford.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediford.

Explore the full profile